ClinicalTrials.gg
RecruitingNCT05319730Updated Oct 7, 2026

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

A Phase 1/2 interventional study of Paclitaxel and Irinotecan in Esophageal Squamous Cell Carcinoma, sponsored by Merck Sharp & Dohme LLC. Recruiting at 58 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Oct 7, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China — 175 open to participants now, 214 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
71st of 352
230 · median 70
Started
2023
with 38 others
Phase 1/2
17 of 402
9 open now
Primary completion
2027-06
later than 134 of 213 live
Registered
184th of 402
by date

Among the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 71st largest by planned enrollment of the 352 interventional ones that give a count, is one of 39 that started in 2023, is one of 17 in phase 1/2, reaches primary completion later than 134 of the 213 other live ones, and was the 184th registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 270 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

175 of the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

170 more — sign in →

All 175 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 181 Esophageal Squamous Cell Carcinoma studies recruiting now, 84 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.

Read the detailed description

The master protocol is MK-3475-U06.

As of Protocol Amendment 5, the Pembrolizumab Plus MK-4830 Plus Paclitaxel/Irinotecan arm and the Pembrolizumab Plus MK-4830 Plus Lenvatinib arm are no longer actively enrolling participants.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • Esophageal cancer
  • Programmed Cell Death 1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1 (PDL-1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL-2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • or cytologically confirmed diagnosis of or locally advanced unresectable esophageal squamous cell carcinoma (ESCC)
  • Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy, that includes a platinum agent and previous exposure to an anti-programmed cell death 1 (PD1)/programmed cell death ligand 1 () based immune oncology (IO) therapy
  • Has provided an archival or most recent tumor tissue sample obtained as part of clinical practice
  • Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible

Exclusion criteria

Exclusion Criteria:

  • Direct invasion into adjacent organs such as the aorta or trachea
  • Has experienced weight loss >10% over approximately 2 months prior to first dose of study therapy
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease
  • Has received an agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Known additional that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy
  • Known active central nervous system (CNS) and/or carcinomatous meningitis
  • Participants with (HIV) with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • History of allogenic tissue/solid organ transplant
  • cardiovascular disease within 12 months from first dose of study intervention
  • Has risk for significant gastrointestinal (GI) bleeding such as a serious nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization, significant bleeding disorders, vasculitis, or has had a significant bleeding episode from the GI tract within 12 weeks prior to allocation/randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Active comparator
    Paclitaxel or irinotecan

    Participants receive paclitaxel 80-100 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 every 28-day cycle until progressive disease (PD) or discontinuation, or irinotecan 180 mg/m\^2 IV on day 1 of every 14-day cycle until PD or discontinuation.

    Drug: Paclitaxel · Drug: Irinotecan

  • Experimental
    Pembrolizumab + MK-4830 + paclitaxel or irinotecan

    Participants receive pembrolizumab 200 mg IV once every 3 weeks (Q3W) for up to 35 cycles (cycle=21 days) or until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + paclitaxel 80-100 mg/m\^2 IV on Days 1, 8, and 15 every 28-day cycle until PD or discontinuation or irinotecan 180 mg/m\^2 180 mg/m\^2 on day 1 every 14-day cycle until PD or discontinuation.

    Drug: Paclitaxel · Drug: Irinotecan · Biological: Pembrolizumab · Biological: MK-4830

  • Experimental
    Pembrolizumab + MK-4830 + lenvatinib

    Participants receive pembrolizumab 200 mg IV Q3W up to 35 cycles (cycle=21 days) until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + lenvatinib 20 mg oral administration every day until PD or discontinuation.

    Biological: Pembrolizumab · Biological: MK-4830 · Drug: Lenvatinib

  • Experimental
    Sacituzumab tirumotecan 4 mg/kg

    Participants will receive 4 mg/kg of sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 of each 42-day cycle until discontinuation.

    Biological: Sacituzumab tirumotecan · Drug: Antihistamine · Drug: H2 Receptor Antagonist · Drug: Acetaminophen (or equivalent) · Drug: Dexamethasone (or equivalent) · Drug: Steroid Mouthwash (dexamethasone or equivalent) · Drug: Supportive care measures

  • Experimental
    Sacituzumab tirumotecan 5 mg/kg

    Participants will receive 5 mg/kg of sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 of each 42-day cycle until discontinuation.

    Biological: Sacituzumab tirumotecan · Drug: Antihistamine · Drug: H2 Receptor Antagonist · Drug: Acetaminophen (or equivalent) · Drug: Dexamethasone (or equivalent) · Drug: Steroid Mouthwash (dexamethasone or equivalent) · Drug: Supportive care measures

Interventions

  • 80-100 mg/m\^2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.

  • 180 mg/m\^2 IV infusion, administered on day 1 of every 14-day cycle.

  • BiologicalPembrolizumab

    200 mg IV infusion, administered every Q3W up to 35 infusions.

    Also known as: MK-3475, KEYTRUDA®

  • BiologicalMK-4830

    800 mg IV infusion, administered Q3W up to 35 infusions.

    Also known as: anti-immunoglobulin-like transcript 4 (anti-ILT4)

  • 20 mg oral administration every day.

    Also known as: MK-7902, LENVIMA®

  • 4 mg/kg or 5 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.

    Also known as: SKB264, MK-2870, sac-TMT

  • Administered per product label.

  • DrugH2 Receptor Antagonist

    Administered per product label.

  • Administered per product label.

  • Administered per product label.

  • Administered per product label.

  • DrugSupportive care measures

    Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or ointment may be given as a supportive care for Ocular Surface Toxicity.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) During Safety Lead-in Phase

    A DLT is defined as any drug-related AE according to the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle.

    Time frame: Up to approximately 3 weeks

  2. Number of Participants Who Experienced an Adverse Event (AE) During Safety Lead-in Phase

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 3 weeks

  3. Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in Phase

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

    Time frame: Up to approximately 3 weeks

  4. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 48 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from allocation to the first documented progressive disease (PD) as assessed by RECIST 1.1 or death due to any cause, whichever occurs first. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to approximately 70 months

  2. Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 70 months

  3. Overall Survival (OS)

    OS is defined as the time from the date of allocation to death from any cause.

    Time frame: Up to approximately 70 months

  4. Number of Participants Experiencing at Least One Adverse Event (AE) During the Efficacy Phase

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 70 months

  5. Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 70 months

07

Study locations

48 of 58 sites recruiting
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)
    Tucson, Arizona 85719, United States
    Recruiting
    • Study Coordinator · Contact520-621-2449
  • UCLA Hematology/Oncology - Santa Monica ( Site 4905)
    Los Angeles, California 90404, United States
    Recruiting
    • Study Coordinator · Contact310-570-1453
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 4925)
    East Syracuse, New York 13057, United States
    Recruiting
    • Study Coordinator · Contact315-472-7504
  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907)
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • UPMC Hillman Cancer Center-UPMC ( Site 4904)
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Study Coordinator · Contact816-898-9413
  • Liga Norte Riograndense Contra o Câncer ( Site 4303)
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Study Coordinator · Contact+55 84 4009-5595
  • Hospital Nossa Senhora da Conceição ( Site 4301)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
    Recruiting
    • Study Coordinator · Contact+5551985833768
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300)
    São Paulo, 01246-000, Brazil
    Recruiting
    • Study Coordinator · Contact+551138934656
  • FALP-UIDO ( Site 4400)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56224205098
  • Centro de Oncología de Precisión-Oncology ( Site 4404)
    Santiago, Region M. de Santiago 7560908, Chile
    Recruiting
    • Study Coordinator · Contact+56225189885
  • Clínica las Condes ( Site 4403)
    Santiago, Region M. de Santiago 7591047, Chile
    Completed

    Not enrolling at this site — choose another above.

  • Clínica UC San Carlos de Apoquindo ( Site 4405)
    Santiago, Region M. de Santiago 7620002, Chile
    Recruiting
    • Study Coordinator · Contact+56934271024
  • Anhui Provincial Hospital ( Site 3501)
    Hefei, Anhui 230001, China
    Recruiting
    • Study Coordinator · Contact+8613955195511
  • Beijing Cancer hospital-Digestive Oncology ( Site 3500)
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Study Coordinator · Contact010-88121122
  • The First Affiliated Hospital of Xiamen University ( Site 3516)
    Xiamen, Fujian 361003, China
    Recruiting
    • Study Coordinator · Contact+865922139767
  • The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 3510)
    Xinxiang, Henan 453100, China
    Recruiting
    • Study Coordinator · Contact8613663030446
  • Henan Cancer Hospital ( Site 3518)
    Zhengzhou, Henan 450008, China
    Recruiting
    • Study Coordinator · Contact+8637165587625
  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 3506)
    Huai'an, Jiangsu 223300, China
    Recruiting
    • Study Coordinator · Contact0517-84992012
  • Shanghai Chest Hospital-Esophageal surgery department ( Site 3513)
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
    • Study Coordinator · Contact+86 21 22200000
  • Zhejiang Cancer Hospital-Thoracic oncology ( Site 3511)
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Study Coordinator · Contact86 13858182310
  • HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 4807)
    Erdgeschoss, Free and Hanseatic City of Hamburg 22297, Germany
    Recruiting
    • Study Coordinator · Contact+ 4940360352246
  • Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 4801)
    Frankfurt am Main, Hesse 60488, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Duesseldorf ( Site 4802)
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 4804)
    Berlin, 13353, Germany
    Completed

    Not enrolling at this site — choose another above.

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 3207)
    Meldola, Emilia-Romagna 47014, Italy
    Recruiting
    • Study Coordinator · Contact0543739100
  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3200)
    Milan, Lombardy 20133, Italy
    Recruiting
    • Study Coordinator · Contact390223903835
  • Azienda Ospedaliero Universitaria Pisana ( Site 3206)
    Pisa, Tuscany 56126, Italy
    Recruiting
    • Study Coordinator · Contact+39050992454
  • Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 3203)
    Padova, Veneto 35128, Italy
    Recruiting
    • Study Coordinator · Contact390498215910
  • Ospedale San Raffaele-Oncologia Medica ( Site 3202)
    Milan, 20132, Italy
    Recruiting
    • Study Coordinator · Contact+390226437615
  • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( Site 3201)
    Milan, 20141, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Aichi Cancer Center ( Site 3702)
    Nagoya, Aichi-ken 464-8681, Japan
    Recruiting
    • Study Coordinator · Contact+81-52-762-6111
  • National Cancer Center Hospital East ( Site 3701)
    Kashiwa, Chiba 277-8577, Japan
    Recruiting
    • Study Coordinator · Contact+81-4-7133-1111
  • Saitama Prefectural Cancer Center ( Site 3703)
    Kitaadachi-gun, Saitama 3620806, Japan
    Recruiting
    • Study Coordinator · Contact+81-48-722-1111
  • Shizuoka Cancer Center ( Site 3704)
    Nagaizumi-cho,Sunto-gun, Shizuoka 411-8777, Japan
    Recruiting
    • Study Coordinator · Contact+81-55-989-5222
  • National Cancer Center Hospital ( Site 3700)
    Chuo-ku, Tokyo 104-0045, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-3542-2511
  • Oslo universitetssykehus, Radiumhospitalet ( Site 4501)
    Oslo, 0379, Norway
    Recruiting
    • Study Coordinator · Contact4723026600
  • National University Hospital ( Site 3800)
    Singapore, South West 119074, Singapore
    Recruiting
    • Study Coordinator · Contact+65 6908 2222
  • Asan Medical Center-Department of Oncology ( Site 3901)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230107179
  • Samsung Medical Center-Division of Hematology/Oncology ( Site 3900)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+82234106518
  • Hôpitaux Universitaires de Genève (HUG) ( Site 4702)
    Geneva, Canton of Geneva 1211, Switzerland
    Recruiting
    • Study Coordinator · Contact+41 22 372 29 01
  • Kantonsspital Graubünden-Medizin ( Site 4700)
    Chur, Kanton Graubünden 7000, Switzerland
    Recruiting
    • Study Coordinator · Contact+41 81 256 61 11
  • Chang Gung Memorial Hospital at Kaohsiung ( Site 4003)
    Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan
    Recruiting
    • Study Coordinator · Contact+88677317123x3267
  • China Medical University Hospital ( Site 4007)
    Taichung, 404332, Taiwan
    Recruiting
    • Study Coordinator · Contact+886975680932
  • Taichung Veterans General Hospital-Radiation Oncology ( Site 4008)
    Taichung, 407, Taiwan
    Recruiting
    • Study Coordinator · Contact+886423592525
  • National Cheng Kung University Hospital ( Site 4001)
    Tainan, 704, Taiwan
    Completed

    Not enrolling at this site — choose another above.

  • National Taiwan University Hospital ( Site 4000)
    Taipei, 10002, Taiwan
    Recruiting
    • Study Coordinator · Contact+886223123456
  • Taipei Veterans General Hospital ( Site 4005)
    Taipei, 112, Taiwan
    Recruiting
    • Study Coordinator · Contact+8862287121212573
  • Chang Gung Medical Foundation-Linkou Branch ( Site 4006)
    Taoyuan, 33305, Taiwan
    Recruiting
    • Study Coordinator · Contact+88633281200
  • Faculty of Medicine Siriraj Hospital ( Site 4102)
    Bangkoknoi, Bangkok 10700, Thailand
    Recruiting
    • Study Coordinator · Contact+6624194488
  • Chulalongkorn University ( Site 4104)
    Pathumwan, Bangkok 10330, Thailand
    Recruiting
    • Study Coordinator · Contact+ุ6622564533
  • Songklanagarind hospital ( Site 4105)
    Hat Yai, Changwat Songkhla 90110, Thailand
    Recruiting
    • Study Coordinator · Contact+6674451469
  • Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 3417)
    Adana, 01140, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact00902124444484
  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 3402)
    Ankara, 06230, Turkey (Türkiye)
    Completed

    Not enrolling at this site — choose another above.

  • Memorial Ankara Hastanesi-Medical Oncology ( Site 3408)
    Ankara, 06520, Turkey (Türkiye)
    Completed

    Not enrolling at this site — choose another above.

  • Ankara Bilkent City Hospital-Medical Oncology ( Site 3405)
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact90 312 552 60 00
  • Atatürk Üniversitesi-onkoloji ( Site 3416)
    Erzurum, 25070, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+904423447232
  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3403)
    Istanbul, 34722, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact00902166065200
  • I.E.U. Medical Point Hastanesi-Oncology ( Site 3406)
    Izmir, 35575, Turkey (Türkiye)
    Completed

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Jun 2027, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 8, 2022
StartActual
May 16, 2023
Primary completionEst.
Jun 11, 2027
CompletionEst.
Apr 10, 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
National Cheng Kung University Hospital ( Site 4001) is now Completed
across 2 updates, Oct 2, 2026 – Oct 7, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • National Cheng Kung University Hospital ( Site 4001) · Tainan, TaiwanContact removed •••1107
Oct 2, 2026
Show all 2 updates
  1. Oct 7, 2026
    National Cheng Kung University Hospital ( Site 4001) is now Completed
    + 1 other change: verification date
  2. Oct 2, 2026
    National Cheng Kung University Hospital ( Site 4001) is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Cheng Kung University Hospital ( Site 4001) · Tainan, TaiwanContact removed •••1107

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05319730
Responsible party
Sponsor
First posted
Apr 8, 2022
Start date
May 16, 2023
Primary completion
Jun 11, 2027 (estimated)
Completion
Apr 10, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-ILT4 Monoclonal Antibody MK-4830 · Sacituzumab tirumotecan

Start the discussion